---
schema_version: "secwatch.filing_event.v1"
accession: "0001689375-25-000041"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:38:10.839802+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Entrada Therapeutics reports Q2 net loss of $43.1M; cash runway into Q2 2027; advances DMD trials

## Summary
- Net loss of $43.1M in Q2 2025 vs net income of $55.0M in Q2 2024; collaboration revenue fell from $94.7M to $2.0M.
- Cash, cash equivalents and marketable securities $354M as of June 30, 2025; expected runway into Q2 2027.
- First patient dosed in ELEVATE-44-201 for DMD exon 44; data from first cohort expected H1 2026.
- Initiated ELEVATE-45-201 for exon 45; first patient dosing on track Q3 2025; cohort 1 data mid-2026.
- Expanded leadership: Navid Khan as SVP Medical Affairs, Kiran Patki as SVP Clinical Development; Maha Radhakrishnan joined Board.

## SEC filing metadata
- accession: 0001689375-25-000041
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000168937525000041/0001689375-25-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000168937525000041/trda-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689375-25-000041
- JSON: https://secwatch.observer/filing/0001689375-25-000041.json
- Plain text: https://secwatch.observer/filing/0001689375-25-000041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.